CINECA IRIS Institutional Research Information System

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.

SAGLIO, Giuseppe;
2011-01-01
2011
THE LANCET ONCOLOGY
12
9
841
851
Administration, Oral; Antineoplastic Agents; Australia; Benzamides; Brazil; Disease-Free Survival; Drug Administration Schedule; Europe; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Singapore; Survival Rate; Time Factors; Treatment Outcome; United States; Philadelphia Chromosome; Oncology
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP.
03A-Articolo su Rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/157962
Citazioni
  • ???jsp.display-item.citation.pmc??? 161
  • Scopus 416
  • ???jsp.display-item.citation.isi??? 381
social impact